Skip to main content
Premium Trial:

Request an Annual Quote

Roche's First-Half Dx Sales Rise 7 Percent; Double-Digit Growth for Applied Science

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today reported that first-half 2010 sales for its diagnostics division increased 7 percent, with its applied science unit posting 11 percent growth for the period.

The Swiss pharmaceuticals, diagnostics, and research products giant reported overall revenues of CHF 24.64 billion ($23.6 billion), up 3 percent from CHF 24.01 billion for the first half of 2009.

Its diagnostics division had 7 percent sales growth to CHF 5.25 billion, with tissue diagnostics and applied science providing the strongest growth at 13 percent and 11 percent, respectively. The firm's molecular diagnostics sales increased 2 percent to CHF 604 million.

Roche said that within its applied science business, cell analysis products had particularly strong growth. The firm did not mention its sequencing products sales in a statement accompanying its financial results.

Roche's pharmaceutical sales were up 1 percent for the period at CHF 19.39 billion.

Overall, Roche's net income for the first half was up 37 percent at CHF 5.56 billion, or CHF 6.91 per share, from CHF 4.05 billion, or CHF 6.32 per share.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.